**Core Concept**
The question is testing the understanding of targeted therapy and its impact on cancer management. **Imatinib**, a tyrosine kinase inhibitor, has revolutionized the treatment of a specific type of cancer by selectively targeting a key enzyme involved in its pathogenesis.

**Why the Correct Answer is Right**
Imatinib specifically targets the BCR-ABL tyrosine kinase, which is a result of the Philadelphia chromosome translocation in chronic myeloid leukemia (CML) cells. By inhibiting this enzyme, imatinib prevents the proliferation of CML cells, leading to a significant improvement in patient outcomes. The introduction of imatinib has dramatically increased the survival rate of patients with CML, making it a prime example of targeted therapy in oncology.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect as imatinib is not primarily used in the management of acute lymphoblastic leukemia (ALL), although it may be used in certain cases of ALL with the Philadelphia chromosome.
* **Option B:** This option is incorrect as imatinib is not used in the management of non-Hodgkin lymphoma (NHL); other targeted therapies and chemotherapies are used instead.
* **Option C:** This option is incorrect as imatinib is not used in the management of breast cancer; other targeted therapies and chemotherapies are used instead.

**Clinical Pearl / High-Yield Fact**
Imatinib is a classic example of a targeted therapy that has significantly improved patient outcomes in CML. It is essential to remember that targeted therapies are designed to selectively target specific molecular mechanisms involved in cancer pathogenesis, making them more effective and less toxic than traditional chemotherapies.

**Correct Answer:** C.